GB Sciences has created a pipeline for the development of novel medicines that are complex mixtures of compounds derived from the Cannabis plant. GBS Global Biopharma, Inc., owned by GB Sciences, now has:
- Four patents that are issued in the US with corresponding patents issued internationally
- Seven nonprovisional patent applications and four provisional patent are pending in the US
- Three licensed patents
- An additional 29 patent applications filed internationally.